The role of c-kit and imatinib mesylate in uveal melanoma

Journal of Carcinogenesis

Volumn 4, Issue , 2005, Pages

  Pereira, Patricia Rusa ^a,b   Odashiro, Alexandre Nakao ^a,b,c   Marshall, Jean Claude ^a,b   Correa, Zelia Maria ^a,b   Belfort, Rubens ^a   Burnier Jr , Miguel N ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b MCGILL UNIVERSITY   (Canada)

^c NONE   (Canada)

Author keywords

C kit; CD117; Gleevec ; Imatinib mesylate; Melanoma; Ocular; Uveal

Indexed keywords

IMATINIB; STEM CELL FACTOR;

ANALYSIS OF VARIANCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANADA; CANCER INHIBITION; CANCER INVASION; CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; MELANOCYTE; STATISTICAL SIGNIFICANCE; UVEA MELANOMA;

EID: 27744550052     PISSN: 14773163     EISSN: 14773163     Source Type: Journal    
DOI: 10.1186/1477-3163-4-19     Document Type: Article

References (31)

1. McLean IW, Armed Forces Institute of Pathology (U.S.), Universities Associated for Research and Education in Pathology.: Tumors of the eye and ocular adnexa. Washington, D.C. Bethesda, Md.: Armed Forces Institute of Pathology ; under the auspices of Universities Associated for Research and Education in Pathology Inc.; 1994.
2. Egan KM, Seddon JM, Glynn RJ, Gragoudas ES, Albert DM: Epidemiologic aspects of uveal melanoma. Surv Ophthalmol 1988, 32(4):239-251.
3. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001, 119(5):670-676.
4. Morstyn G, Brown S, Gordon M, Crawford J, Demetri G, Rich W, McGuire B, Foote M, McNiece I: Stem cell factor is a potent synergistic factor in hematopoiesis. Oncology 1994, 51(2):205-214.
5. Yarden Y, Kuang WJ, Yang-Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A: Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. Embo J 1987, 6(11):3341-3351.
6. Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L et al: Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders. Cancer 2003, 97(11):2760-2766.
7. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP et al: Diagnosis of gastrointestinal stromal tumors: A consensus approach. Hum Pathol 2002, 33(5):459-465.
8. Lefevre G, Glotin AL, Calipel A, Mouriaux F, Tran T, Kherrouche Z, Maurage CA, Auclair C, Mascarelli F: Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem 2004, 279(30):31769-31779.
9. de Silva CM, Reid R: Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res 2003, 9(1):13-19.
10. McGary EC, Onn A, Mills L, Heimberger A, Eton O, Thomas GW, Shtivelband M, Bar-Eli M: Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo. J Invest Dermatol 2004, 122(2):400-405.
11. Diebold Y, Blanco G, Saornil MA, Fernandez N, Lazaro MC: Morphologic and immunocytochemical characterization of four human uveal cell lines (melanoma-and melanocytes-derived). Curr Eye Res 1997, 16(5):487-495.
12. De Waard-Siebinga I, Blom DJ, Griffioen M, Schrier PI, Hoogendoorn E, Beverstock G, Danen EH, Jager MJ: Establishment and characterization of an uveal-melanoma cell line. Int J Cancer 1995, 62(2):155-161.
13. Woodward JK, Elshaw SR, Murray AK, Nichols CE, Cross N, Laws D, Rennie IG, Sisley K: Stimulation and inhibition of uveal melanoma invasion by HGF, GRO, IL-1alpha and TGF-beta. Invest Ophthalmol Vis Sci 2002, 43(10):3144-3152.
14. Druker BJ: Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work? J Natl Cancer Inst 2002, 94(22):1660-1661.
15. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990, 82(13):1107-1112.
16. All-Ericsson C, Girnita L, Muller-Brunotte A, Brodin B, Seregard S, Ostman A, Larsson O: c-Kit-dependent growth of uveal melanoma cells: a potential therapeutic target? Invest Ophthalmol Vis Sci 2004, 45(7):2075-2082.
17. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD: A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004, 103(8):3222-3225.
18. Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, Kris MG, Pizzo B, Tyson L, Dunne M et al: Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein. Cancer 2005, 103(10):2128-2131.
19. Petit A, Castillo M, Santos M, Mellado B, Alcover JB, Mallofre C: KIT expression in chromophobe renal cell carcinoma: comparative immunohistochemical analysis of KIT expression in different renal cell neoplasms. Am J Surg Pathol 2004, 28(5):676-678.
20. Potti A, Hille RC, Koch M: Immunohistochemical determination of HER-2/neu overexpression in malignant melanoma reveals no prognostic value, while c-Kit (CD117) overexpression exhibits potential therapeutic implications. J Carcinog 2003, 2(1):8.
21. Mouriaux F, Kherrouche Z, Maurage CA, Demailly FX, Labalette P, Saule S: Expression of the c-kit receptor in choroidal melanomas. Melanoma Res 2003, 13(2):161-166.
22. Tzen CY, Mau BL: Analysis of CD117-negative gastrointestinal stromal tumors. World J Gastroenterol 2005, 11(7):1052-1055.
23. Bauer S, Hartmann JT, de Wit M, Lang H, Grabellus F, Antoch G, Niebel W, Erhard J, Ebeling P, Zeth M et al: Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 2005.
24. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos AP, Emile JF, Gronchi A, Hogendoorn PC, Joensuu H et al: Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol 2005, 16(4):566-578.
25. Candelaria M, de la Garza J, Duenas-Gonzalez A: A Clinical and Biological Overview of Gastrointestinal Stromal Tumors. Med Oncol 2005, 22(1):1-10.
26. Stefanou D, Batistatou A, Zioga A, Arkoumani E, Papachristou DJ, Agnantis NJ: Immunohistochemical expression of vascular endothelial growth factor (VEGF) and C-KIT in cutaneous melanocytic lesions. Int J Surg Pathol 2004, 12(2):133-138.
27. Guerriere-Kovach PM, Hunt EL, Patterson JW, Glembocki DJ, English JC, 3rd, Wick MR: Primary melanoma of the skin and cutaneous melanomatous metastases: comparative histologic features and immunophenotypes. Am J Clin Pathol 2004, 122(1):70-77.
28. Romagnoli S, Graziani D, Bramerio M, Gambacorta M, Colombo P, Roncalli M, Coggi G, Bosari S: Immunohistochemical profile and c-kit mutations in gastrointestinal stromal tumors. Pathol Res Pract 2005, 201(2):71-81.
29. Pache M, Glatz K, Bosch D, Dirnhofer S, Mirlacher M, Simon R, Schraml P, Rufle A, Flammer J, Sauter G et al: Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays. Virchows Arch 2003, 443(6):741-744.
30. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ, Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000, 295(1):139-145.
31. Damato B: Developments in the management of uveal melanoma. Clin Experiment Ophthalmol 2004, 32(6):639-647.